• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Carvedilol may be new therapeutic strategy for canine heart disease

January 1, 2002

The past 15 years have seen a resurgence of interest and developments in new medical therapies for congestive heart failure (CHF).

The past 15 years have seen a resurgence of interest and developmentsin new medical therapies for congestive heart failure (CHF).

Neurohormonal antagonism has become a primary strategy for combatingthe mechanisms that contribute to progressive cardiac dysfunction. Beta-andrenergicreceptor blockers are some of the newer agents used for this purpose.

Neurohormonal changes

Increased sympathetic nervous system (SNS) tone and decreased parasympatheticactivity characterize some of the neurohormonal changes that accompany CHF.

While these changes result in short term increases in cardiac outputand blood pressure, they have deleterious chronic effects, including cardiachypertrophy and remodeling, increased afterload, myocardial fibrosis/necrosis,and induction of cardiac arrhythmias. Beta blockade limits these harmfuleffects, decreases morbidity and improves long-term survival in humans withCHF secondary to a variety of causes.

Beneficial properties

Carvedilol was the first beta-blocker approved for the treatment of CHFin human patients.

This non-selective beta blocker (blocks ß1 and ß2 receptors)has several unique properties that may help explain its beneficial effectsin heart failure patients.

Carvedilol also blocks 1 receptors, decreasing peripheral vascular resistance(the drug was originally evaluated as an antihypertensive agent). Carvedilolhas antioxidant properties, actively scavenging oxygen-free radicals inhumans and dogs. The drug also acts as an antiarrhythmic agent with ClassII and reportedly Class I actions on ventricular myocytes.

Use of carvedilol (and other beta-blockers) for the treatment of CHFin humans is commonplace, but experience with the drug is limited in veterinarymedicine. Dr. Robert Hamlin and his research team have recently evaluatedthe pharmacology of carvedilol in the dog (pages 57-60 AJVR, Jan 2000, Vol61:1) and presented this and other information at the ACVIM Forum last May(page 107, Proceedings of the 19th Annual Veterinary Medical Forum, 2001.)

Advertisement

Carvedilol has a bioavailability of approximately 10 percent after oraladministration in dogs, and most (95 percent) of the drug is protein bound.It is lipophilic and accumulates in cell membranes. The major routes ofmetabolism are in the liver and >75 percent is excreted in the feces.Only 8 percent of the compound is excreted in urine. Doses up to 1.25 mg/kgare well tolerated, achieving peak plasma concentrations two to four hoursafter oral administration.

Veterinary uses

Given carvedilol's multiple pharmacologic effects, it has several potentialuses in veterinary cardiology patients. Early and continued interest hasfocused on its use in dogs with myocardial systolic dysfunction, primarilyidiopathic dilated cardiomyopathy.

The first reported improvements in clinical condition and survival inhumans were in such patients. As all beta-blockers have negative inotropiceffects, careful patient selection is required before prescribing carvedilolin dogs with dilated cardiomyopathy.

The author has adopted a human protocol of upward titration startingat 3.125 mg PO BID <25 kg) or 25 mg BID (patients >25 kg.) The ownersare instructed to monitor for symptoms of cardiac decompensation (lethargy,tachypnea, coughing) during the titration period. Carvedilol is contraindicatedin unstable cardiac patients. The drug must be used with extreme cautionin patients with severe myocardial systolic dysfunction (i.e. shorteningfraction <15 percent), as it may precipitate congestive heart failurein an otherwise compensated patient.

Carvedilol is theoretically an ideal agent for treatment of doxorubicincardiotoxicity. This chemotherapeutic agent causes myocyte damage throughthe generation of oxygen free radicals, resulting in cardiac electricaldisturbances and myocardial failure. The disease is progressive and oftenresults in death from cardiac causes.

Carvedilol's antioxidant properties, antiarrhythmic effects and antagonismof the SNS make it ideally suited to treat patients with doxorubicin-inducedcardiac disease.

Carvedilol may prove useful in the treatment of cardiac arrhythmias aswell. The author has documented antiarrhythmic efficacy (>80 percentreduction in ventricular ectopy as measured by 24-Holter recordings) ina Doberman Pinscher and Boxer with dilated cardiomyopathy treated with carvedilol.

Despite overwhelming support for the use of this drug in human patientsand anecdotal reports of efficacy in dogs, objective data supporting theuse of carvedilol in veterinary patients are lacking and await the resultsof veterinary clinical trials. New research is also evaluating the use ofthis drug in dogs with myxomatous valvular degeneration. Results of thesestudies may soon add carvedilol to the armamentarium of drugs availableto the veterinary practitioner to treat patients with congestive heart failure.


Advertisement

Latest News

News wrap-up: This week’s headlines, plus dvm360® launches its first CE podcast

Educating clients on brachycephalic breeds

Viticus group seeks applications for veterinary boot camp scholarship

Unusual parasite strain kills 4 California sea otters

View More Latest News
Advertisement